- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
AJMC® in the Press, August 3, 2018
Coverage of our peer-reviewed research and news reporting in the healthcare and mainstream press.
Providing a comprehensive round up of updates coming out of the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, Evidence-Based Oncology™, a sister publication of The American Journal of Managed Care® (AJMC®), has released its ASCO recap issue. The issue was promoted by The Daily Times, a daily newspaper in Tennessee. Highlighted updates include findings from the TAILORx trial for breast cancer and an update on chimeric antigen receptor T-cell therapy.
The National Pharmaceutical Council’s Monday CER Daily Newsfeed mentioned 2 articles from AJMC®. The article, “Value-Based Pricing Is in Place, but Prices for a Single Drug Vary,” covers a study that offered caution as value-based pricing gains traction in the US healthcare market. The authors say distinctions in both method and likelihood of improving aligning prices with value should be carefully considered. Reporting on the FDA’s guidance on electronic record (EHR) data use, the article “FDA Finalizes Guidance on Use of EHR Data in Clinical Investigations,” outlines the recommendations and best practices provided in the guidance.
In a press release on the opening of new MDVIP-affiliated practices, a study from AJMC® on the personalized healthcare model was highlighted. The study, “Personalized Preventive Care Leads to Significant Reductions in Hospital Utilization,” assessed the impact of the MDVIP model on hospital utilization and found that MDVIP members’ rates were significantly lower than nonmembers’.
Examining Low-Value Cancer Care Trends Amidst the COVID-19 Pandemic
April 25th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the April 2024 issue of The American Journal of Managed Care® about their findings on the rates of low-value cancer care services throughout the COVID-19 pandemic.
Listen
Lack of Mutations Associated With Favorable Prognosis in MPN-U
April 25th 2024While the Dynamic International Prognostic Scoring System and bone marrow blasts may predict overall survival, the lack of certain mutations is also associated with a better prognosis for myeloproliferative neoplasm, unclassifiable (MPN-U).
Read More
What We’re Reading: FDA Approves UTI Antibiotic; Ozempic, Wegovy Price Investigation; US Births Fall
April 25th 2024The FDA recently approved an antibiotic for the treatment of urinary tract infections (UTIs) in women; a Senate committee recently launched an investigation into the prices of Novo Nordisk’s diabetes and weight loss drugs; US births fell last year, resuming a national slide after a previous increase during the pandemic.
Read More
